Ubiquitin variant modulators of SCF E3 ligases and their uses

Patent metadata

Field	Value
Publication number	US-10618942-B2
Application number	US-201715436337-A
Country	US
Kind code	B2
Filing date	Feb 17, 2017
Priority date	Feb 17, 2016
Publication date	Apr 14, 2020
Grant date	Apr 14, 2020

Abstract

The invention provides ubiquitin variants that specifically bind to SCF E3 ligases, and use of these variants to modulate the activity of SCF E3 ligases.

First claim

What is claimed is:

1. A Ubv polypeptide comprising one or more amino acid substitution selected from the group consisting of A12G, I42R or V, L49R, H62Q, R63K, and G75R in the amino acid sequence of Fw7.1, and wherein amino acids 77 and 78 are optional.

2. The Ubv polypeptide of claim 1 , comprising the following substitutions: A12G, I42V, L49R, H62Q, R63K, I72V, R74G, G75R, and G76R (Fw7.5), and wherein amino acids 77 and 78 are optional.

3. The Ubv polypeptide of claim 1 , comprising the following substitutions:
(a) A12G, L49R, H62Q, R63K, R74P, and G75S (Fw7.6);
(b) A12G, I42R, S46A, R47G, K48R, L49R, H62Q, R63K, L71Y, I72V, and G75R (Fw7.7);
(c) I42R, S46A, R47G, H62Q, R63K, L71W, I72F, F73L, G75F, and G76V (Fw7.8);
(d) A12G, L49R, H62Q, R63K, L71M, I72V, R74S, and G75K (Fw7.9);
(e) A9T, A12G, I42V, I44L, L49V, H62Q, R63K, L71W, I72L, F73L, and G75R (Fw7.10);
(f) E36G, I42V, R47K, L49R, H62Q, R63K, and G75R (Fw7.11);
(g) I42R, S46A, R47G, L49R, H62Q, R63K, I72L, G75R, and G76E (Fw7.12);
(h) A9S, A12G, E36G, I44L, L49R, H62Q, R63K, R74S, and G76A (Fw7.13);
(i) E36D, I42V, I44L, S46R, L49K, H62Q, R63K, V70L, L71W, F73V, and G75R (Fw7.14);
(j) A12G, R47H, K48M, L49R, H62Q, R63K, and R74S (Fw.7.15);
(k) A12G, E36G, I44L, L49P, H62Q, R63K, L71V, I72V, and G75R (Fw7.16);
(l) A12G, E36G, I42R, S46A, R47G, L49R, H62Q, R63K, and T66S (Fw7.17); or
(m) I42R, L49R, H62Q, R63K, I72L, and R74P (Fw7.18);
wherein amino acids 77 and 78 are optional.

4. A Ubv polypeptide comprising the amino acid sequence of Fw11.1 (SEQ ID NO:20), wherein the sequence of Fw11.1 optionally has 1-5 substitutions.

5. The Ubv polypeptide of claim 4 , comprising the following substitutions:
(a) S12Y, S14T, and N17H (Fw11.2; SEQ ID NO:21);
(b) S14T and Y15F (Fw11.3; SEQ ID NO:22);
(c) S12Y (Fw11.4; SEQ ID NO:23);
(d) S14T (Fw11.5; SEQ ID NO:24);
(e) S14T, Y15F, and N17D (Fw11.6; SEQ ID NO:25);
(f) S14T and N17H (Fw11.7; SEQ ID NO:26);
(g) S12Y and S14T (Fw11.8; SEQ ID NO:27);
(h) Y15F (Fw11.9; SEQ ID NO:28);
(i) N17H (Fw11.10; SEQ ID NO:29);
(j) S14N and Y15F (Fw11.11; SEQ ID NO:30);
(k) N17D (Fw11.12; SEQ ID NO:31);
(l) S12H and N17Y (Fw11.13; SEQ ID NO:32);
(m) S12Y and S15F (Fw11.14; SEQ ID NO:33);
(n) K11R and S14T (Fw11.15; SEQ ID NO:34);
(o) S12T (Fw11.16; SEQ ID NO:35); or
(p) S12A (Fw11.17; SEQ ID NO:36).

6. A UbV polypeptide comprising a sequence selected from the group consisting of SEQ ID NOs:2-36, or a variant thereof comprising a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:2-36, or a fragment thereof.

7. A nucleic acid molecule encoding a Ubv polypeptide of claim 1 .

8. A nucleic acid molecule encoding a Ubv polypeptide of claim 4 .

9. A nucleic acid molecule encoding a Ubv polypeptide of claim 6 .

Assignees

• Governing Council Univ Toronto

Inventors

• Gorelik Maryna
• Sidhu Sachdev

Classifications

• C07K14/00

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof · CPC title

• C12N9/93 Primary

  Ligases (6) · CPC title

• G01N33/5008

  for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics · CPC title

• C12N15/1058

  Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms · CPC title

• C07K7/08

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title